Literature DB >> 2365821

Significant phenylalanine hydroxylation in vivo in patients with classical phenylketonuria.

G N Thompson1, D Halliday.   

Abstract

Indirect measurements have previously suggested that patients with classical phenylketonuria (PKU) do not convert significant amounts of phenylalanine to tyrosine. Low-dose continuous infusion techniques employing [2H5]phenylalanine and [2H2]tyrosine were used to quantitate in vivo phenylalanine hydroxylation in 10 subjects with classical phenylketonuria, 2 with hyperphenylalaninemia (HPA), and 7 controls. Plasma phenylalanine concentration ranged from 523 to 1,540 mumols/liter in PKU, 402 to 533 in HPA, and 49 to 54 in controls. Subjects with classical PKU hydroxylated mean +/- SD 4.8 +/- 2.2 mumols/kg per h (range 0.9-8.4) of phenylalanine to tyrosine and those with HPA 4.4 and 5.3, respectively. These rates were substantial in comparison with those in controls (6.3 +/- 1.6, 3.2-8.2). The significant hydroxylation in PKU and HPA subjects is likely to result from induction of activity of tyrosine hydroxylase towards phenylalanine by the greatly elevated phenylalanine concentration. The presence of such activity in PKU suggests that therapy aimed at promotion of this usually latent hydroxylating capacity may be a future alternative to dietary treatment of PKU.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2365821      PMCID: PMC296723          DOI: 10.1172/JCI114701

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Phenylalanine hydroxylase activity in liver biopsies from hyperphenylalaninemia heterozygotes: deviation from proportionality with gene dosage.

Authors:  S Kaufman; E E Max; E S Kang
Journal:  Pediatr Res       Date:  1975-08       Impact factor: 3.756

2.  Quantitative studies on the urinary excretion of unconjugated aromatic acids in phenylketonuria.

Authors:  R A Chalmers; R W Watts
Journal:  Clin Chim Acta       Date:  1974-09-30       Impact factor: 3.786

3.  Phenylketonuria: reduction of serum levels of phenylalanine following oral administration of B-2 thienylalanine.

Authors:  C Krips; D R Lines
Journal:  Aust Paediatr J       Date:  1972-12

4.  Urinary amino acid excretion in phenylketonuric, hyperphenylalaninemic, and normal patients.

Authors:  D R Lines; H A Waisman
Journal:  J Pediatr       Date:  1971-03       Impact factor: 4.406

5.  Solubilization and partial purification of tyrosine hydroxylase from bovine adrenal medulla.

Authors:  R Shiman; M Akino; S Kaufman
Journal:  J Biol Chem       Date:  1971-03-10       Impact factor: 5.157

6.  Tolerance of phenylalanine after ntravenous administration in phenylketonurics, heterozygous carriers, and normal adults.

Authors:  H J Bremer; W Neumann
Journal:  Nature       Date:  1966-03-12       Impact factor: 49.962

7.  Determination of phenylalanine hydroxylase activity in patients with phenylketonuria and hyperphenylalaninemia.

Authors:  K Bartholomé; P Lutz; H Bickel
Journal:  Pediatr Res       Date:  1975-12       Impact factor: 3.756

8.  Classic phenylketonuria: diagnosis through heterozygote detection.

Authors:  R F Griffin; L J Elsas
Journal:  J Pediatr       Date:  1975-04       Impact factor: 4.406

9.  Detection of hepatic phenylalanine 4-hydroxylase in classical phenylketonuria.

Authors:  P A Friedman; D B Fisher; E S Kang; S Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-02       Impact factor: 11.205

10.  Whole-body leucine and lysine metabolism: response to dietary protein intake in young men.

Authors:  K J Motil; D E Matthews; D M Bier; J F Burke; H N Munro; V R Young
Journal:  Am J Physiol       Date:  1981-06
View more
  12 in total

Review 1.  Uses of stable isotopes in clinical diagnosis and research in the paediatric population.

Authors:  O A Bodamer; D Halliday
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

2.  Recurrent nonsense mutation in exon 7 of the phenylalanine hydroxylase gene.

Authors:  B Dworniczak; L Kalaydjieva; C Aulehla-Scholz; K Ullrich; I Kremensky; B Radeva; J Horst
Journal:  Hum Genet       Date:  1991-10       Impact factor: 4.132

Review 3.  Techniques for studying hepatic metabolism in vivo.

Authors:  J V Leonard; G N Thompson
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

4.  Modelling amino acid metabolism.

Authors:  M Hjelm; J Seakins
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

5.  In vivo disposal of phenylalanine in phenylketonuria: a study of two siblings.

Authors:  E Treacy; J J Pitt; K Seller; G N Thompson; S Ramus; R G Cotton
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

6.  A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients.

Authors:  S Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

7.  An ongoing debate over phenylalanine hydroxylase deficiency in phenylketonuria.

Authors:  C R Scriver
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

8.  Phenylketonuria. The in vivo hydroxylation rate of phenylalanine into tyrosine is decreased.

Authors:  F J van Spronsen; D J Reijngoud; G P Smit; G T Nagel; F Stellaard; R Berger; H S Heymans
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

9.  The investigation of inborn errors in vivo using stable isotopes.

Authors:  J V Leonard; S J Heales
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

10.  PKU mutations R408Q and F299C in Norway: haplotype associations, geographic distributions and phenotype characteristics.

Authors:  H G Eiken; K Stangeland; L Skjelkvåle; P M Knappskog; H Boman; J Apold
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.